These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 19028406)

  • 1. Dermatologic symptoms associated with the multikinase inhibitor sorafenib.
    Robert C; Mateus C; Spatz A; Wechsler J; Escudier B
    J Am Acad Dermatol; 2009 Feb; 60(2):299-305. PubMed ID: 19028406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
    Autier J; Escudier B; Wechsler J; Spatz A; Robert C
    Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of dermatological toxicities associated with sorafenib.
    Zhang L; Zhou Q; Ma L; Wu Z; Wang Y
    Clin Exp Dermatol; 2011 Jun; 36(4):344-50. PubMed ID: 21507035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
    Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
    Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
    Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
    Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
    Diamantis ML; Chon SY
    J Drugs Dermatol; 2010 Feb; 9(2):169-71. PubMed ID: 20214183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
    J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localized dyskeratotic plaque with milia associated with sorafenib.
    Chappell JA; Burkemper NM; Semchyshyn N
    J Drugs Dermatol; 2009 Jun; 8(6):573-6. PubMed ID: 19537383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
    Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
    Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib-associated hand-foot syndrome in Japanese patients.
    Iijima M; Fukino K; Adachi M; Tsukamoto T; Murai M; Naito S; Minami H; Furuse J; Akaza H
    J Dermatol; 2011 Mar; 38(3):261-6. PubMed ID: 21342228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib tosylate in advanced kidney cancer: past, present and future.
    Porta C; Paglino C; Imarisio I; Ferraris E
    Anticancer Drugs; 2009 Jul; 20(6):409-15. PubMed ID: 19436197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib-induced palmoplantar hyperkeratosis.
    Lountzis NI; Maroon MS
    J Drugs Dermatol; 2008 Jun; 7(6):588-9. PubMed ID: 18561593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors.
    Smith KJ; Haley H; Hamza S; Skelton HG
    Dermatol Surg; 2009 Nov; 35(11):1766-70. PubMed ID: 19660024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials.
    Takimoto CH; Awada A
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):535-48. PubMed ID: 18026728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma.
    Hütten M; Lassay L; Sachs B; Deutz P; Mertens R; Baron JM; Merk HF; Ott H
    Pediatr Dermatol; 2009; 26(3):349-50. PubMed ID: 19706105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
    J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
    Wood LS; Manchen B
    Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma.
    Ikeda M; Fujita T; Mii S; Tanabe K; Tabata K; Matsumoto K; Satoh T; Iwamura M
    Jpn J Clin Oncol; 2012 Sep; 42(9):820-4. PubMed ID: 22782962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
    Strumberg D; Awada A; Hirte H; Clark JW; Seeber S; Piccart P; Hofstra E; Voliotis D; Christensen O; Brueckner A; Schwartz B
    Eur J Cancer; 2006 Mar; 42(4):548-56. PubMed ID: 16426838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.